GLAND · Back to the company page
Investment Brief
Evidence through Sep 2026The business
Customers are innovators and specialty pharmaceutical companies in regulated markets; US revenue for the half-year was βΉ2,161 crore, up 37%, Europe and other regulated markets revenue was βΉ411 crore, up 23%, rest-of-world revenue was βΉ204 crore and India revenue was βΉ38.7 crore.
What is changing
- CDMO revenue grew 31% year-on-year to βΉ823 crore and contributed about 45% of total revenue, driven by commercial supply of previously signed contracts, new launches and new development and manufacturing partnerships.
- US revenue grew 42% year-on-year to βΉ1,180 crore in the quarter and 37% to βΉ2,161 crore in the half-year, helped by new product launches and newer CDMO business.
Recent events
Catalysts
| Catalyst | Timing | Size | What has to go right |
|---|---|---|---|
| US FDA inspection of the additional bag manufacturing line, after which products from the line could be commercialized and the capacity constraint eased. | β | β | The inspection has to conclude so that the line can be used for commercial supply. |
| NUPCO tender results from Saudi Arabia, which management says are delayed. | β | β | The tender has to be announced; management says it has participated with about 13 products and is confident of winning products in that segment. |
Strengths
- CDMO growth and mix
CDMO revenue grew 31% year-on-year to βΉ823 crore and contributed about 45% of total revenue, with margins described as better than the regular business by about 5% to 10%. - US portfolio expansion
The company launched products in the US in the quarter, filed 11 ANDAs and received 10 approvals, bringing cumulative US ANDA filings to 399 with 350 approved and 49 pending.
Risks
- Capacity constraints
Management says it is struggling for capacity in ophthalmic, bags and liquid vials, with liquid vial utilization already at 92% and anticipated at close to 102% next year. - Tender and supply timing
Performance was impacted by market-specific supply and tender dynamics, especially the delay of NUPCO tender results from Saudi Arabia, and by lower volumes due to delayed tender business in the Middle East.
Competitive position
On operating margin, the company's 27.3% is above the peer median of 13.5% for the 241 companies in the peer group with a value, ranking 37 of 241.
| Metric | GLAND | Peer median | Rank |
|---|---|---|---|
| Operating margin | 27.3% | 13.5% | 37 of 241 |
| Return on capital employed | 15.1% | 12.5% | 97 of 242 |
| Return on equity | 10.7% | 10.5% | 115 of 236 |
Compared with 248 companies in Pharmaceuticals & Biotechnology (medians; data as of 15 Nov 2026). Rank 1 is best, except price multiples, where 1 is lowest.
Latest quarter
| Sep 2026 | Latest | vs year ago | vs prior quarter |
|---|---|---|---|
| Revenue | βΉ1,834 cr | 23.3% | 1.9% |
| EBITDA | βΉ484 cr | 54.1% | -1.0% |
| Profit after tax | βΉ291 cr | 58.2% | -8.2% |
- Over the trailing twelve months revenue was βΉ7,072 crore, EBITDA was βΉ1,921 crore and profit after tax was βΉ1,236 crore, an EBITDA margin of 27.2%.
What the price requires
Market capitalisation βΉ55,016 cr Β· trailing 12-month profit after tax βΉ1,236 cr Β· price-to-earnings 44.5x
| Assumed yearly return to shareholders | Profit needed at the end | Implied yearly profit growth |
|---|---|---|
| 12.0% | βΉ1,737 cr | 12.0% |
A calculation, not a forecast: 3-year horizon, the multiple unchanged and a constant share count.
Ownership and deals
| Holder | Sep 2026 | Jun 2026 | Change |
|---|---|---|---|
| Promoters | 45.8% | 51.8% | β6.0 pp |
| Foreign institutions | 10.4% | 8.7% | +1.6 pp |
| Domestic institutions | 33.2% | 30.4% | +2.8 pp |
- On 4 Sep 2026, Fosun Pharma Industrial Pte. Ltd. disclosed a disposal of 6.0% of the company.
Facts from company filings, exchange data and company documents, with calculations shown. Educational information; not investment advice.